Hyderabad, July 30 : Dr. Reddy’s Laboratories Limited said that it has entered into a licensing agreement with Princeton, New Jersey based Slayback Pharma LLC to acquire rights in Slayback’s Brimonidine Tartrate Ophthalmic Solution 0.025 percent, the private label equivalent of Lumify in U.S.
Lumify is an Over-The-counter (OTC) eye drop that can be used to relieve redness of the eye due to minor eye irritations.
The agreement also provides Dr. Reddy’s exclusive rights to the product outside the U.S, Hyderabad-based pharma giant said in a release here on Saturday.
Slayback Pharma is the first company to file an ANDA for the private label equivalent for Lumify with the USFDA under Paragraph IV certification.
The ANDA is currently under USFDA review and covers Brimonidine Tartrate Ophthalmic Solution 0.025 percent in 2.5 ml and 7.5 ml fill volumes.
“We are pleased to license this important OTC ophthalmic product for the U.S. market,” said Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s.
“This product complements Dr. Reddy’s growing OTC product portfolio in the eyecare category that includes the private label versions of Pataday® Once Daily Relief and Pataday® Twice Daily Relief,” Marc added.
